Altimmune, Inc.
NASDAQ:ALTBiotechnology
+$0.08 today
- Market cap
- $270.48M
- Beta
- 0.23
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$0.73
Volume 4.69M
Average 3.81M
ALT Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Altimmune, Inc.NASDAQ: ALT
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables dips below year-ago levels
Q1 FY2026 accounts receivables of $72K fell 94.6% year over year, behind the +2450.0% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -14.5% a year.
Context
- Accounts receivables amounted to 5026.8% of revenue in FY2025, down 3653.2 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -94.6% toward the trailing-twelve-month pace of +2450.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 2.06M USD
- Year-over-year change
- +18.7%
- 4-year CAGR
- -25.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.06M | +18.7% |
| FY2024 | 2024-12-31 | 1.74M | +175.1% |
| FY2023 | 2023-12-31 | (2.31M) | -170.1% |
| FY2022 | 2022-12-31 | 3.3M | -49.5% |
| FY2021 | 2021-12-31 | 6.53M | — |
Accounts Receivables vs competitors
How ALT compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +2450.0% is the 2nd highest of 6, against a peer median of -70.9%.
- Accounts receivables amounts to 2219.4% of revenue for ALT, versus a peer median of 18.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $177.45M USD | -18642.7% | — | 92.7% | |
| LTM Jun 2026 | $100.3M USD | — | — | — | |
| LTM Mar 2026 | $32.8M USD | +4000.1% | +39.1% | 47.4% | |
| FY2025 | €816.45K EUR | -70.9% | -40.3% | 18.2% | |
| LTM Mar 2026 | $799K USD | +2450.0% | -14.5% | 2219.4% | |
| LTM Mar 2026 | $451K USD | -1148.8% | +17.0% | 0.6% | |
| LTM Mar 2026 | $0 USD | +100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding ALT) | — | -70.9% | +17.0% | 18.2% | |
Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (97.09M) | (84.71M) | (88.45M) | (95.06M) | (88.09M) |
| Depreciation & Amortization | 551K | 493K | 477K | 238K | 112K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (681K) |
| Stock-Based Compensation | 5.52M | 8.1M | 10.64M | 14.39M | 16.08M |
| Change in Working Capital | (251K) | 14.11M | (8.27M) | 4.48M | 6.75M |
| Accounts Receivables | 6.53M | 3.3M | (2.31M) | 1.74M | 2.06M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.42M | 2.77M | (2.73M) | (1.86M) | 2.51M |
| Other Working Capital | (8.21M) | 8.04M | (3.23M) | 4.6M | 2.19M |
| Other Non-Cash Items | 13.03M | (578K) | 9.79M | (3.9M) | (1.7M) |
| Operating Cash Flow | (78.24M) | (62.59M) | (75.81M) | (79.85M) | (67.54M) |
| Capital Expenditures | (12.31M) | (126K) | (47K) | 0 | (11K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (7.59M) | (73.27M) | (88.63M) | (115.73M) | (285.45M) |
| Sales of Investments | 107.43M | 0 | 102.41M | 87.35M | 152.99M |
| Other Investing Activities | (195K) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 87.52M | (73.4M) | 13.73M | (28.39M) | (132.47M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 33.92M |
| Common Stock Issued | 65.04M | 56.35M | 86.6M | 9.99M | 173.73M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 58K | 434K | (496K) | 50K | (709K) |
| Financing Cash Flow | 65.1M | 56.78M | 86.11M | 10.04M | 206.84M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 74.38M | (79.2M) | 24.03M | (98.19M) | 6.83M |
| Free Cash Flow | (90.55M) | (62.71M) | (75.86M) | (79.85M) | (67.55M) |
Altimmune, Inc.
NASDAQ:ALT
Intrinsic Alpha fair value
Locked
Current Price
$1.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.